Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3
Authors:
- 1 February 2016
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 136 (2) , 464-472
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3Journal of Clinical Investigation, 2013
- BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of ResistanceClinical Cancer Research, 2012
- Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemiaCell Cycle, 2011
- NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferationPigment Cell & Melanoma Research, 2009
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- ErbB receptors and the development of the nervous systemExperimental Cell Research, 2009
- Gastrointestinal stem cells in development and cancerThe Journal of Pathology, 2008
- Notch1 is an effector of Akt and hypoxia in melanoma developmentJournal of Clinical Investigation, 2008
- Role of nuclear factor-κ B in melanomaCancer and Metastasis Reviews, 2005
- The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous systemGenes & Development, 1998